PMOS across the ages

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The lifespan picture described in this article is unchanged by the rename; if anything, the metabolic centrality reflected in the new name makes the post-reproductive-age framing more visible than the old name supported.

The most common and most misleading thing people with PMOS hear about the condition is that it "gets better with age." Cycles do often become more regular in the late 30s and 40s. Some androgenic features soften. People feel relief and assume the condition is fading.

It is not. It is shifting. The reproductive markers that define PMOS in the 20s become less loud as ovarian function changes through perimenopause. The metabolic and cardiovascular features often become more consequential during the same years. Understanding the shift is how the condition stays a managed picture across decades, rather than an undetected one that re-emerges as a different diagnosis later.

Why PMOS looks different at different ages

PMOS is not a single static condition. It is a pattern of insulin, androgen, and ovarian dysregulation that expresses itself through whichever hormonal system is most active at a given life stage:

• Puberty foregrounds cycle and skin features.
• The reproductive years foreground fertility and ongoing androgenic features.
• Perimenopause foregrounds metabolic markers and the transition itself.
• Post-menopause foregrounds long-term cardiovascular and endometrial considerations.

The underlying biology (typically insulin resistance contributing to androgen excess, with the parallel adrenal source contributing in approximately 20 to 30 percent of cases) does not disappear. What changes is which body system is loudest about it.

Adolescence (roughly 12 to 19)

What tends to be loud:Acne that persists past typical adolescent acne. Cycles that do not settle into a pattern by 2 to 3 years post-menarche. Unwanted hair growth. Body changes that feel different from peers’ trajectories. Mood and body-image patterns that often get attributed to "normal teen experience" and miss being recognised as part of an emerging condition.

What the current guideline says: The 2023 International Guideline recommends deferring the formal PMOS label in adolescents (cycle irregularity is developmentally typical in the first 2 to 3 years post-menarche) while not deferring the workup or management when symptoms are present. The 2025 Peña et al. adolescent extension to the Guideline refined this further: foundational support, metabolic screening, and mental health attention can begin without waiting for the diagnostic threshold.

What to watch for: early metabolic engagement, mental health support, and disordered-eating-adjacent vigilance. The 2023 Guideline names disordered eating risk explicitly in adolescent PMOS; restrictive interventions in this age range are documented to cause more harm than they resolve.

The 20s (the diagnosis years)

What tends to be loud: Cycles that are long, skipped, or unpredictable. Acne and body and facial hair persisting into adult life. Body changes that feel harder to manage than they should. Fertility questions starting to surface.

The clinical reality: Most PMOS diagnoses happen in this decade, often during a workup for something else (fertility planning, contraception conversation, dermatology referral). Insulin resistance is often emerging but not always flagged. The standard panel that gets ordered in primary care typically misses the metabolic side.

What to watch for: A complete workup including fasting insulin (not just fasting glucose), free testosterone with SHBG, and DHEA-S for the adrenal source contribution. The care-prep guide on PMOS diagnosis covers the full panel. Many people in their 20s with PMOS are prediabetic on labs without ever having been screened, because routine panels do not include insulin.

The 30s (the pivot)

What tends to be loud: Cycles may begin to regulate (this is not the same as improvement; see below). Weight and body changes feel harder to engage with than they did in the 20s. Cravings become more prominent. Fertility becomes the active question for those trying to conceive. Fatigue, mood, and sleep quality often worsen. Hairline thinning may appear or accelerate.

The clinical reality: The 30s are where metabolic risk compounds. The 2023 Guideline supports more intensive monitoring of blood pressure, lipid profile, fasting glucose, and HbA1c than in the general population. Pregnancy in PMOS carries elevated rates of gestational diabetes and hypertensive disorders, which the fertility pillar covers in depth.

What to watch for: Periodic comprehensive metabolic screening, even when symptoms feel quieter. Pre-conception planning if relevant. Mental health attention, which often comes up around this transition.

The 40s and beyond (the long game)

What tends to be loud:Cycle irregularity often eases as the follicle pool declines toward perimenopause. This is the "it gets better" framing many people with PMOS hear from clinicians, and it is the one that most often goes badly. Androgenic features may soften but do not disappear. Meanwhile, type 2 diabetes risk, cardiovascular disease risk, hypertension, metabolic syndrome, obstructive sleep apnoea, and endometrial cancer risk (from years of anovulation without adequate progesterone exposure) all accumulate.

The clinical reality: PMOS does not retire. The 2023 International Guideline specifically addresses post-menopausal management, including continued monitoring for metabolic and cardiovascular disease, endometrial surveillance where relevant, and ongoing attention to androgenic features that persist. Annual labs including insulin-sensitivity markers remain meaningful.

Improving cycles with age is not a resolution of the condition. It is one set of features quieting while a different, often more consequential set emerges. The shift is the part that matters most for long-term care.

What to watch for: Cardiovascular and diabetes prevention as the primary screening focus. Endometrial surveillance if there have been long stretches of anovulation without progesterone exposure. Conversations about menopausal hormone therapy (sometimes called HRT) when perimenopause is approaching. Continued symptom management for androgenic features where present.

What the longitudinal data show

Longitudinal studies of women with PMOS consistently show several patterns across the lifespan:

• Cycle irregularity typically improves in the late 30s and 40s, even before menopause. This is a real and expected ovarian-aging shift; it does not reflect a change in the underlying insulin-androgen axis.
• Type 2 diabetes risk is approximately 3 to 5 times higher in women with PMOS than in the general population, with the divergence becoming most pronounced in the 30s and 40s.
• Cardiovascular disease risk is elevated across multiple markers (inflammation, lipids, blood pressure, arterial stiffness). Mortality data are still maturing, but the markers consistently point in the same direction.
• Endometrial cancer risk is approximately 2 to 3 times elevated, primarily in patients with extended periods of anovulation without adequate progesterone exposure.
• Mental health conditions (anxiety, depression, disordered eating) occur at elevated rates across the lifespan, often with peaks corresponding to diagnosis, fertility transitions, and perimenopause.

These are population-level patterns. They are not predictions for any individual. They do shape what the standard of care looks like across decades.

What this means for how PMOS gets managed

The practical implication of the lifespan picture is that PMOS care is not a one-time setup. The most effective care is revisited every few years because the priority shifts:

In the teens and 20s: cycle regulation if needed, attention to androgenic features, baseline metabolic screening even when symptoms feel manageable, mental health support, disordered-eating-adjacent vigilance.

In the 30s: fertility planning if relevant, more intensive metabolic monitoring, pregnancy-specific care where applicable, continued attention to ongoing features.

In the 40s: cardiovascular and diabetes prevention as primary screening focus, endometrial surveillance where relevant, conversations about hormone therapy as perimenopause approaches, continued attention to features that persist.

Post-menopause: long-term cardiovascular and metabolic care, bone health, ongoing metabolic maintenance, attention to androgenic features that may continue.

Instead of asking "is my PMOS getting better?" (a question hard to answer meaningfully), the more useful framing is: Given my age and current state, what is the most important thing to screen for and manage right now? That question turns PMOS from a yes-or-no condition into a moving target that can be actively tracked.

Why this matters for how PMOS gets framed

The cultural framing of PMOS (and of PCOS before it) as a "fertility and skin condition of young women" is a generation behind the evidence. It is a lifelong metabolic, hormonal, and cardiovascular condition that also affects fertility and skin, particularly in young adulthood.

The cost of the old framing shows up in the 40s and 50s, when many people with PMOS get told their condition is "gone" while their insulin resistance quietly progresses into prediabetes or type 2 diabetes. The condition did not resolve. It stopped showing up in the places clinicians were trained to look.

The 2026 rename is part of why this is changing. Naming the condition more accurately as a polyendocrine metabolic ovarian syndrome makes the lifespan picture harder to dismiss. The reproductive features remain part of the picture; the metabolic and cardiovascular features sit alongside them, not after them, across decades.

Staying curious about what PMOS is showing at the current age, with the current labs and current features, is a more useful stance than waiting for it to resolve.